BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) ( www.BSDMedical.com), a leading provider of medical systems that utilize targeted heat therapy to treat cancer, announced today that the Cancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (WRMC), located in Goodyear, Arizona, has purchased a BSD-2000 Hyperthermia System (BSD-2000). WRMC serves the Western United States, including the major metropolitan areas of Phoenix, Denver, Los Angeles, Las Vegas, Seattle, Portland and Albuquerque. This will be the eighth BSD Hyperthermia system purchased by CTCA ®. WRMC is a state-of-the-art, all-digital cancer hospital that provides advanced cancer treatments, world-class technologies and integrative therapies under one roof. The 213,000-square-foot facility is located on a 25-acre site, which is part of the Phoenix metropolitan area. Like the other CTCA cancer hospitals, WRMC provides the most advanced therapeutic resources in cancer treatment ( http://www.cancercenter.com/western-hospital/about-western/history.cfm). CTCA is a network of hospitals and one of the premier providers of cancer care in the world. CTCA physicians specialize in treating many types of cancer, including complex and advanced stage cases. CTCA is committed to revolutionizing cancer care by providing the most advanced and effective cancer treatments and integrative therapies available in order to treat the cancer and improve the patient’s treatment experience and quality of life. The CTCA hospitals were recently recognized by the Commission on Cancer of the American College of Surgeons as "offering the very best in cancer care." About the BSD-2000 Hyperthermia System The BSD-2000 – developed and patented exclusively by BSD – delivers localized therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The BSD-2000 creates a central focusing of energy that can be electronically focused to target the shape, size, and location of the tumor, thus providing dynamic control of the heating delivered to the tumor region. The BSD-2000 has Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and Drug Administration (FDA) for use in conjunction with radiation therapy for the treatment of cervical cancer patients who are ineligible for chemotherapy. The BSD-2000 also has CE (Conformité Européenne) Marking approval for the commercial sale in Europe. CE Marking approval is also recognized in many countries outside of the EU.